Nordion Appoints Mr. Grant Gardiner as SVP and General Counsel

  Nordion Appoints Mr. Grant Gardiner as SVP and General Counsel

Business Wire

OTTAWA, Ontario -- January 28, 2013

Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services to the global health science market, today announced it is appointing
Grant Gardiner as Senior Vice President, General Counsel & Corporate
Secretary. Mr. Gardiner will serve as the Corporation's legal officer
responsible for all global legal matters, effective March 18, 2013.

"We are very pleased to welcome Grant to the Nordion management team. With
more than 19 years of experience, Grant is a seasoned lawyer with a strong
understanding of business and global market dynamics. His proven expertise in
leading cross-listed, publicly traded companies through complex legal,
governance and compliance landscapes with a business focus will be a
significant asset to Nordion,” said Mr. Steve West, Chief Executive Officer,
Nordion Inc. “Grant is expected to play an instrumental role in the execution
of our business strategy globally.”

Mr. Gardiner joins Nordion from Research in Motion Limited (RIM) where he
currently serves as Vice-President, Associate General Counsel and acted as
Corporate Secretary to RIM’s Board of Directors for approximately four years.
During his tenure at RIM, which began in 2008, Grant has advised on securities
matters, mergers & acquisitions, ethics and compliance programs as well as
Board and Corporate Governance matters.

With leadership roles at other leading global, publicly-traded companies such
as Cognos Inc. (now IBM) and JDS Uniphase, Mr. Gardiner’s experience includes
mergers and acquisitions, corporate governance, commercial transactions, as
well as securities and anti-corruption law. He holds a Bachelor of Business
Administration from the University of Prince Edward Island (1988), an L.L.B.
from Osgoode Hall Law School (1991) and was admitted to the Ontario Bar in
1993.

About Nordion Inc.

Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that
provides market-leading products used for the prevention, diagnosis and
treatment of disease. We are a leading provider of targeted therapies,
sterilization technologies, and medical isotopes that benefit the lives of
millions of people in more than 60 countries around the world. Our products
are used daily by pharmaceutical and biotechnology companies, medical-device
manufacturers, hospitals, clinics and research laboratories. Nordion has
approximately 500 highly skilled employees worldwide. Find out more at
www.nordion.com and follow us at http://twitter.com/NordionInc.

Forward-Looking Statements

Certain statements contained in this news release constitute "forward-looking
statements". These statements are based on current beliefs and assumptions of
management, however are subject to known and unknown risks, uncertainties and
other factors that may cause actual results to differ materially from the
forward-looking statements in this news release. For additional information
with respect to certain of these beliefs, assumptions, risks and
uncertainties, please refer to Nordion’s Annual Information Form for fiscal
2012 available on SEDAR at www.sedar.com and on EDGAR on www.sec.gov.

Contact:

Nordion
INVESTORS:
Ana Raman, 613-595-4580
investor.relations@nordion.com
or
MEDIA:
Tamra Benjamin, 613-592-3400 x 1022
tamra.benjamin@nordion.com
 
Press spacebar to pause and continue. Press esc to stop.